Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Patient education · Psoriasis / Topical Per AAD-NPF 2021 + UpToDate 2024 · Updated 2026-05-09

Topical therapy for psoriasis
Steroids, vitamin D analogs, and special-site protocols

Topical therapy controls 80% of mild-moderate psoriasis. Three pillars per AAD-NPF 2021 (Elmets): (1) topical corticosteroids (potency 1-7 by site), (2) vitamin D analogs (calcipotriol/calcitriol, often combined with steroid in fixed-dose products like Daivobet®), (3) special-site protocols for face/intertriginous (TCI), scalp (foams/solutions), nail (intralesional steroid), palmoplantar. This article covers fingertip-unit dosing, proactive maintenance, and step-up criteria.

Note: Topical strength selection and duration must be individualized by a dermatologist based on lesion site, severity, age. Long-term or large-area super-potent steroid use can cause skin atrophy; conversely, under-treatment leads to chronic flares. This page is patient education only.
Key Fact (Elmets 2021, JAAD)

Topicals control 70–80% of mild-to-moderate psoriasis — the most-prescribed and most cost-effective therapy under Taiwan NHI. However, if topicals fail to control after 6 months, or lesions are located on special sites (face / folds / scalp / genitals / nails) impair quality of life, or BSA > 10%, then escalation to phototherapy or systemic treatment is indicated. "Psoriasis rebound" typically occurs after abrupt discontinuation of potent topical steroids, tapering should be gradual or switch to vitamin D analog for maintenance.

When are topicals first-line?

For mild (BSA ≤ 3%) to moderate (BSA 3–10%) psoriasis. Even patients on phototherapy or biologics use topicals for residual plaques and special sites. Step up to phototherapy/systemic when BSA > 10%, PASI > 10, DLQI > 10, or after 6 months of inadequate topical control.

Topical corticosteroids — the cornerstone

Class 1 (super-potent: clobetasol 0.05%) for thick plaques, palms/soles, scalp; class 2–3 (potent: betamethasone dipropionate, mometasone) for body; class 4–5 (mid) for trunk/limbs; class 6–7 (low: hydrocortisone, desonide) for face, intertriginous, genitalia, children. Use the fingertip unit (FTU): 1 FTU ≈ 0.5 g covers 2 adult palms (≈ 2% BSA). Induction 2–4 weeks daily-BID, then taper to weekend pulsing plus weekday vitamin D analog. Avoid super-potent steroids > 4 weeks continuously. Side effects: atrophy, telangiectasia, striae, tachyphylaxis, rebound (may trigger GPP).

Vitamin D analogs

Calcipotriol/calcipotriene 50 mcg/g, calcitriol 3 mcg/g, and combination calcipotriol/betamethasone (Daivobet/Taclonex) — all AAD-NPF 2021 strong recommendations. Combination foam/gel/ointment is the most convenient and reaches 60–70% clearance. Weekly limit 100 g calcipotriol to avoid hypercalcemia. Do not co-apply with salicylic acid (degrades calcipotriol). Calcitriol is less irritating on the face.

Other topicals

Tazarotene 0.05–0.1% (retinoid) — irritation, contraindicated in pregnancy; combine with steroid. Tacrolimus / pimecrolimus — preferred for face, genitalia, intertriginous; long-term maintenance, no atrophy. Salicylic acid 2–10% — keratolytic for thick scalp/palmoplantar plaques. Coal tar — effective shampoo for scalp.

Special-site protocols

  • Face / genitalia / intertriginous: tacrolimus or pimecrolimus first-line; low-potency steroid for short-term flare control; avoid potent steroids and tazarotene.
  • Scalp: salicylic acid soak overnight, potent steroid shampoo/foam/solution, calcipotriol scalp solution, combination Daivobet gel; coal tar shampoo as adjunct.
  • Palmoplantar: super-potent steroid + occlusion; salicylic acid keratolysis; consider tazarotene, acitretin, PUVA bath, biologics if refractory.
  • Nail: intralesional triamcinolone (2.5–5 mg/mL) into proximal nail fold every 4–8 weeks; topical calcipotriol/tazarotene to nail folds. Step up to systemics/biologics if multiple nails or QoL impact.

Smart combinations

AM steroid + PM vitamin D, fixed-combination calcipotriol/betamethasone, induction with steroid then maintenance with TCI/vit D, and topical + phototherapy. Combinations outperform monotherapy for both efficacy and side-effect profile.

Bottom line

Topicals control 70–80% of mild-to-moderate psoriasis. Use potent steroids briefly, avoid them on thin skin, prefer vitamin D for maintenance, and step up promptly when special sites or 6-month-resistant disease persist.